Tuberculosis research and development: seeding the future

Affiliations

¹ Global TB Programme, WHO, Geneva 1211, Switzerland. Electronic address: lienhardtc@who.int.
² Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
³ Global TB Programme, WHO, Geneva 1211, Switzerland.
⁴ Treatment Action Group, New York, NY, USA.
⁵ Medical Research Council South Africa, Cape Town, South Africa.
⁶ Prévessin-Moëns, France.

Free article

Comment

Christian Lienhardt et al. Lancet Respir Med. 2018 Apr.

Free article

. 2018 Apr;6(4):242-244.

doi: 10.1016/S2213-2600(18)30050-X.

¹ Global TB Programme, WHO, Geneva 1211, Switzerland. Electronic address: lienhardtc@who.int.
² Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
³ Global TB Programme, WHO, Geneva 1211, Switzerland.
⁴ Treatment Action Group, New York, NY, USA.
⁵ Medical Research Council South Africa, Cape Town, South Africa.
⁶ Prévessin-Moëns, France.

No abstract available

Comment on

The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.
Floyd K, Glaziou P, Zumla A, Raviglione M. Floyd K, et al. Lancet Respir Med. 2018 Apr;6(4):299-314. doi: 10.1016/S2213-2600(18)30057-2. Lancet Respir Med. 2018. PMID: 29595511 Review.